Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
Andres ChangAkil AktharSusanne L LindermanLilin LaiVictor Manuel Orellana-NoiaRajesh M ValanparambilHasan AhmedVeronika I ZarnitsynaAshley Alesia McCookJeffrey M SwitchenkoJean L KoffKristie A BlumAmy A AyersColin B O'LearyMichael C ChurnetskiShahana SulaimanMelissa KivesPreston ShengCarl W DavisAjay K NookaMorie A GertzMadhav V DhodapkarMehul S SutharJonathon B CohenRajesh M ValanparambilPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Antibody binding and live-virus neutralization against SARS-CoV-2 and its variants of concern including Delta and Omicron were substantially lower in patients with NHL/CLL compared with healthy vaccinees. Anti-CD20-directed therapy < 1 year before vaccination and number of circulating B cells strongly predict vaccine response.